MicroBiome TherapeuticsTM LLC, (MBT) has announced positive top-line results from the company's clinical trial of lead microbiome modulator NM504 in development for type 2 diabetes and prediabetes. NM504 is designed to improve glucose tolerance and other metabolic parameters in patients with diabetes by shifting the gastrointestinal (GI) microbiome. Studies have shown that type 2 diabetics typically have GI dysbiosis, or microbial imbalances, that may contribute to the metabolic dysfunction associated with the condition.
No comments:
Post a Comment